GICS Sector : Healthcare
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States.The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
If You Could Only Hold 3 Investments for Life, Consider These
Mar -10
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment
Feb -19
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Shareholders to Inquire about Securities Investigation
Feb -14
Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Shareholders to Connect
Feb -13
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Shareholders to Reach Out
Feb -12
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Shareholders to Learn More About the Investigation
Feb -11
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Stockholders to Inquire about Securities Investigation
Feb -10
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Investors to Learn More About the Investigation
Feb -09
Inari Medical's 8.9% growth in Venous Thromboembolism treatment is driven by increasing adoption of minimally invasive procedures, growing demand for clot removal devices, and expanding indications for thrombectomy. Additionally, rising awareness of VTE risks, improved patient outcomes, and increasing market penetration in emerging economies contribute to the growth.
Inari Medical's Emerging Therapies segment growth is driven by increasing adoption of ClotTriever and FlowTriever systems, expanding treatment of deep vein thrombosis and pulmonary embolism, and growing demand for minimally invasive procedures. Strong clinical data, regulatory approvals, and strategic partnerships also contribute to the 9.95% growth.
A device used to remove large clot burdens from peripheral arteries, allowing for the restoration of blood flow.
A device used to remove blood clots from peripheral arteries and veins, allowing for the restoration of blood flow.
Inari Medical, Inc. faces moderate threat from substitutes due to the availability of alternative treatments for venous diseases.
Inari Medical, Inc. has a diverse customer base, which reduces the bargaining power of individual customers.
Inari Medical, Inc. relies on a few key suppliers for critical components, which gives them some bargaining power.
Inari Medical, Inc. operates in a highly regulated industry, which creates barriers to entry for new entrants.
Inari Medical, Inc. operates in a competitive industry with several established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 6.45% |
| Debt Cost | 3.95% |
| Equity Weight | 93.55% |
| Equity Cost | 8.59% |
| WACC | 8.29% |
| Leverage | 6.89% |
Value: 0.2
Growth: 9.6
Quality: 6.5
Yield: 0.0
Momentum: 8.0
Volatility: 6.3
1-Year Total Return ->
Value: 6.0
Growth: 8.0
Quality: 4.5
Yield: 0.0
Momentum: 10.0
Volatility: 2.0
1-Year Total Return ->
Value: 6.4
Growth: 6.4
Quality: 5.9
Yield: 3.0
Momentum: 2.0
Volatility: 5.0
1-Year Total Return ->
Value: 4.2
Growth: 6.1
Quality: 3.1
Yield: 0.0
Momentum: 10.0
Volatility: 4.0
1-Year Total Return ->
Value: 6.4
Growth: 2.3
Quality: 5.9
Yield: 0.0
Momentum: 3.0
Volatility: 5.0
1-Year Total Return ->
Value: 9.0
Growth: 2.3
Quality: 3.5
Yield: 0.0
Momentum: 2.0
Volatility: 2.7
1-Year Total Return ->